Sensei Biotherapeutics names Anand Parikh CEO, replacing Christopher Gerry

• Sensei Biotherapeutics outlined board and senior management changes tied to stockholder votes scheduled for June 10, 2026.
• Directors Christopher W. Gerry, Thomas Ricks, Kristian Humer submitted conditional resignations effective two business days after annual meeting, contingent on approval of share issuance tied to conversion of Series B Non-Voting Convertible Preferred Stock and a charter amendment to expand authorized common shares to 300,000,000 from 12,500,000.
• Board set conditional appointments of Stephen M. Hahn, Saira Ramasastry, Karen Vousden to take effect at same time if proposals pass.
• Board expects to name Chief Operating Officer Anand Parikh as chief executive officer, replacing President and General Counsel Christopher W. Gerry as principal executive officer.
• Board also expects to appoint Head of Operations and Finance Brian Stephenson as chief financial officer, replacing Senior Vice President of Finance Josiah Craver as principal financial officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-158951), on April 16, 2026, and is solely responsible for the information contained therein.